Disease-Vaccine-Landing-Page/side-panel

In June 2022, the FDA authorized use of a 25mcg Moderna COVID-19 mRNA vaccine in infants and children ages six months through five years, to be given as a 2-dose...

In June 2022, the FDA authorized use of two doses of a 100mcg Moderna COVID-19 mRNA vaccine in adolescents 12 through 17 years of age and two doses of a...

Moderna COVID-19 Vaccine Trial Data in AdultsOn May 18, 2020, Moderna, Inc. of Cambridge, Massachusetts announced that it had obtained “positive interim clinical data” from a Phase 1 human clinical...

According to data released December 27, 2024 by the CDC, reports received by VAERS for the Pfizer-BioNTech experimental COVID-19 vaccine totaled 968,551 vaccine adverse events with 218,696 categorized as serious....

On June 17, 2022, the FDA authorized use of a 3mcg dose of Pfizer-BioNTech COVID-19 vaccine for use in children six months through four years of age, to be given...

On May 10, 2021, the FDA expanded the EUA granted Pfizer/BioNTech to distribute its experimental mRNA vaccine in the U.S. to include administration to children as young as 12 years...

Original Pfizer - BioNTech Vaccine Trial Safety DataMore than 50 percent of adult participants involved in the Phase 1/2 human trials of Pfizer and BioNTech’s experimental messenger RNA (ribonucleic acid)...

Under EUA authority, the FDA Commissioner may permit “unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious...

An article published on September 30, 2021 in the European Journal of Epidemiology reported that vaccination has had no impact on COVID-19 rates. According to the published data that looked...

There is evidence that COVID-19 vaccination can increase a person’s risk of COVID-19 illness immediately following vaccination. A pre-print study posted in February 2021 that examined Israeli vaccination data reported...